Re: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction - Reply

被引：0
|
作者：
Abrams, P.
Kaplan, S.
De Koning Gans, H. J.
Millard, R.
机构：
来源：
JOURNAL OF UROLOGY | 2006年 / 176卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2312 / 2313
页数：2
相关论文
共 50 条
  • [41] THERAPEUTIC EFFICACY AND SAFETY OF MIRABEGRON MONOTHERAPY IN MALE OVERACTIVE BLADDER PATIENTS WITH AND WITHOUT BLADDER OUTLET OBSTRUCTION
    Liao, C.
    Lee, C.
    Lee, Y.
    Kuo, H.
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 : S80 - S82
  • [42] Tolterodine promising for overactive bladder
    Magee, J
    LANCET, 2000, 355 (9213): : 1434 - 1434
  • [43] Re: Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder
    Kaplan, Steven A.
    JOURNAL OF UROLOGY, 2022, 208 (04): : 908 - 908
  • [44] Tolterodine for the treatment of overactive bladder: A six-year safety data update
    Garely, AD
    Molinari, M
    Wang, JT
    Guan, ZH
    OBSTETRICS AND GYNECOLOGY, 2004, 103 (04): : 89S - 90S
  • [45] Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients
    Takei, M
    Homma, Y
    INTERNATIONAL JOURNAL OF UROLOGY, 2005, 12 (05) : 456 - 464
  • [46] Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK
    Morant, S. V.
    Reilly, K.
    Bloomfield, G. A.
    Chapple, C.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (05) : 688 - 694
  • [47] The evolution of obstruction induced overactive bladder symptoms following urethrolysis for female bladder outlet obstruction
    Starkman, Jonathan S.
    Duffy, John W., III
    Wolter, Christopher E.
    Kaufman, Melissa R.
    Scarpero, Harriette M.
    Dmochowski, Roger R.
    JOURNAL OF UROLOGY, 2008, 179 (03): : 1018 - 1023
  • [48] Tolterodine - A review of its use in the treatment of overactive bladder
    Clemett, D
    Jarvis, B
    DRUGS & AGING, 2001, 18 (04) : 277 - 304
  • [49] A pharmacoeconomic evaluation of oxybutynin and tolterodine for the treatment of overactive bladder
    Ko, Y
    Malone, DC
    Armstrong, EP
    VALUE IN HEALTH, 2005, 8 (03) : 414 - 415
  • [50] Tolterodine once-daily in treatment of the overactive bladder
    Appell, RA
    Anderson, R
    Diokno, AC
    Dmochowski, R
    Staskin, D
    UROLOGY, 2001, 58 (05) : 830 - 831
12345